Let's see what this stock has announced on Thursday. The post ASX 200 healthcare stock sinks 9% on FDA update appeared first ...

AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.

Senate Democrats are advancing a new prescription drug pricing agenda they say would lower costs for patients, reduce wasteful health care spending, and strengthen US biomedical innovation, while ...

This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

More than 1,583 new HIV infections were recorded in 2024 in a country with a population of less than 1 million.

Feb 4 GNA-The Country Observers Mission on Governance (COMoG), has raised concern over increasing arrests of individuals ...

HANGZHOU CITY, ZHEJIANG, CHINA, January 19, 2026 /EINPresswire.com/ -- With the development of the pharmaceutical and ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

Terremoto Biosciences is a company making waves in the drug development world. They’re using a pretty cool approach to create new medicines, focusing on how molecules interact at a chemical level.

GSK on Wednesday forecast slower sales growth in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries ...

Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials ...